Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Inhaled HH-120 in Mild to Moderate COVID-19
NCT06039163Phase 1Completed
- Sponsor
- Huahui Health
- Start
- Apr 2022
- Primary completion
- Oct 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing HH-120 with Placebo (2 arms). Primary endpoints: Treatment-Emergent Adverse Events, Treatment-Related Adverse Events and 1 more. Started Apr 2022; status: completed.
02
Drugs
HH-120
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06039163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06039163.